Merck & Co., Inc. (MRK) — 分析摘要
Merck & Co., Inc.（MRK）的市值为376.37十亿美元，最近一年的营收同比增长了+1.3%。净利润率为28.1%。当前市盈率为118.6倍。
核心要点
- 营收同比变化+1.3%
- 净利润率28.1%
- 市盈率118.6倍
与PHARMACEUTICAL PREPARATIONS板块的其他公司相比，MRK的营收增长为+1.3%，市盈率为118.6倍。
Merck & Co., Inc. (MRK)
更新 — ET · 市场数据 POLYGON · 财务数据 SEC EDGAR
红旗与风险提示高风险信号
存在多项实质性红旗，在依赖任何估值输出前应先重点核查这些风险。
利息保障倍数为 0.0x — 盈利不足以覆盖利息支出
Debt/EBITDA 为 4.9x — 杠杆偏高
净利润较上一期下降 82.6%。
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. In cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 53% of the company's 2025 sales were generated from US human health (pharmaceuticals and vaccines).
行业
PHARMACEUTICAL PREPARATIONS
员工人数
75,000
总部
RAHWAY, NJ
Exchange
XNYS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
年度每股股息
$3.40
股息收益率
2.23%
股息历史
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。